Revenue scaled from $9.1M to $57.9M and gross margin expanded from 35.0% to 76.5% over recent quarters, but trailing net margin remains negative at -5.8%, suggesting profitability is not yet consistent.
Eton Pharmaceuticals, Inc. (ETON) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 141.06M | 79.95M | 39.01M | 31.64M | 21.25M | 21.83M | 39K | 959K | 0 | 0 |
| Revenue Growth % | 100.61% | 104.94% | 23.29% | 48.9% | -2.66% | 55879.49% | -95.93% | - | - | - |
| Cost of Goods Sold | 43.51M | 37.21M | 15.6M | 10.58M | 6.93M | 2.62M | 286K | 453K | 63K | 13K |
| COGS % of Revenue | - | 46.54% | 39.99% | 33.44% | 32.62% | 12.01% | 733.33% | 47.24% | - | - |
| Gross Profit | 97.55M | 42.74M | 23.41M | 21.06M | 14.32M | 19.21M | -247K | 506K | -63K | -13K |
| Gross Margin % | 69.15% | 53.46% | 60.01% | 66.56% | 67.38% | 87.99% | -633.33% | 52.76% | - | - |
| Gross Profit Growth % | - | 82.56% | 11.16% | 47.09% | -25.46% | 7876.92% | -148.81% | 903.17% | -384.62% | - |
| Operating Expenses | 56.86M | 42.67M | 26.01M | 22.25M | 22.58M | 20.7M | 26.86M | 19.11M | 10.32M | 7.14M |
| OpEx % of Revenue | - | 53.37% | 66.67% | 70.33% | 106.24% | 94.83% | 68882.05% | 1992.39% | - | - |
| Selling, General & Admin | 46.95M | 35.82M | 22.75M | 18.93M | 18.58M | 14.47M | 12.76M | 7.55M | 4.69M | 3.21M |
| SG&A % of Revenue | - | 44.8% | 58.32% | 59.83% | 87.44% | 66.27% | 32717.95% | 787.49% | - | - |
| Research & Development | 9.92M | 7.76M | 3.25M | 3.32M | 4M | 6.24M | 14.1M | 11.55M | 5.63M | 3.93M |
| R&D % of Revenue | - | 9.71% | 8.34% | 10.5% | 18.8% | 28.56% | 36164.1% | 1204.9% | - | - |
| Other Operating Expenses | 0 | -916K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 40.69M | 72K | -2.6M | -1.19M | -8.26M | -1.5M | -27.11M | -18.6M | -10.32M | -7.15M |
| Operating Margin % | 28.84% | 0.09% | -6.66% | -3.77% | -38.87% | -6.85% | -69515.38% | -1939.62% | - | - |
| Operating Income Growth % | - | 102.77% | -117.87% | 85.57% | -452.51% | 94.49% | -45.75% | -80.22% | -44.35% | - |
| EBITDA | 45.66M | 4.12M | -1.45M | -291K | -6.49M | -1.03M | -26.46M | -18.15M | -10.26M | -7.14M |
| EBITDA Margin % | 32.37% | 5.15% | -3.72% | -0.92% | -30.52% | -4.73% | -67846.15% | -1893.01% | - | - |
| EBITDA Growth % | 6395.45% | 383.67% | -398.63% | 95.51% | -527.88% | 96.1% | -45.75% | -76.97% | -43.73% | - |
| D&A (Non-Cash Add-back) | 4.98M | 4.04M | 1.15M | 901K | 1.77M | 462K | 651K | 447K | 63K | 13K |
| EBIT | 39.47M | 223K | -1.8M | -689K | -9.02M | -1.96M | -27.11M | -18.6M | -10.32M | -7.16M |
| Net Interest Income | -2.4M | -4.78M | -2M | -1.06M | -955K | -1.04M | -889K | 281K | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 281K | 164K | 52.5K |
| Interest Expense | 2.4M | 4.78M | 2M | 1.06M | 955K | 1.04M | 889K | 0 | 0 | 0 |
| Other Income/Expense | -3.62M | -4.63M | -1.21M | 503K | -761K | -460K | -859K | 281K | -2.42M | -6K |
| Pretax Income | 37.06M | -4.56M | -3.81M | -689K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M | -7.16M |
| Pretax Margin % | 26.27% | -5.7% | -9.76% | -2.18% | -42.45% | -8.95% | -71717.95% | -1910.32% | - | - |
| Income Tax | -12.8M | 43K | 15K | 247K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -34.54% | -0.94% | -0.39% | -35.85% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 49.86M | -4.6M | -3.82M | -936K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M | -7.16M |
| Net Margin % | 35.35% | -5.75% | -9.8% | -2.96% | -42.45% | -8.95% | -71717.95% | -1910.32% | - | - |
| Net Income Growth % | 846.24% | -20.35% | -308.44% | 89.62% | -361.43% | 93.01% | -52.67% | -43.8% | -78.03% | - |
| Net Income (Continuing) | 49.86M | -4.6M | -3.82M | -936K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M | -7.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.50 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | -0.41 |
| EPS Growth % | 711.96% | -13.33% | -310.96% | 89.86% | -363.92% | 94.17% | -30.39% | 48.74% | -385.37% | - |
| EPS (Basic) | - | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | -0.41 |
| Diluted Shares Outstanding | 33.26M | 26.91M | 25.89M | 25.65M | 25.15M | 25.21M | 21.01M | 17.76M | 6.42M | 17.46M |
| Basic Shares Outstanding | 28.66M | 26.91M | 25.89M | 25.64M | 25.15M | 25.21M | 21.01M | 17.76M | 6.42M | 17.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ETON stock.
For fiscal year 2025, Eton Pharmaceuticals, Inc. (ETON) reported total revenue of $80.0M.
Eton Pharmaceuticals, Inc. (ETON) reported a net loss of $4.6M for the fiscal year ending 2025.
Eton Pharmaceuticals, Inc. (ETON) reported an operating income of $0.1M, resulting in an operating profit margin of 0.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Eton Pharmaceuticals, Inc. (ETON) generated $42.7M in gross profit for the year, representing a gross profit margin of 53.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Thin margins and dilution risk
Metrics are mathematically derived from official filings.
Revenue Compounding Through Orphan Product Scale-Up
According to reported quarterly figures, ETON's revenue rose from $9.1M in 2024Q2 to $57.9M in 2026Q3, with the latest quarter up 157.9% year over year, indicating a sharp acceleration in demand for its specialty portfolio.
The progression from roughly $9M to nearly $58M per quarter suggests that orphan and pediatric formulations are gaining real commercial traction rather than reflecting a one-time launch stocking effect. The consistency of triple-digit growth across several quarters points to durable prescription demand, though the base was small and the sequential jump in 2026Q3 warrants scrutiny for wholesaler inventory timing. Investors should monitor whether growth holds once the initial launch cohort matures.
Gross Margin Rebuilt Above Sixty Percent
Based on reported figures, ETON's gross margin expanded from 35.0% in 2025Q3 to 76.5% in 2026Q3, a level that suggests a shift toward higher-value wholly controlled products and better unit economics.
The recovery from the mid-2025 trough implies that mix, rather than pricing alone, is driving improvement, as lower-margin hospital injectables appear to be a diminishing share of revenue. The 2026Q3 figure is notably high relative to the prior 53-63% range, so it may reflect favorable royalty timing or one-off items that should not be extrapolated without confirmation. Sustained margins above 60% would support the premium-niche thesis.
Operating Leverage Emerging but Unproven
As reported in financial statements, ETON's operating margin moved from -7.8% in 2025Q2 to 39.7% in 2026Q3, but trailing operating margin remains near 0.1%, showing that gains have been recent and uneven.
Operating income turning sharply positive in the latest quarter while SG&A rose only modestly relative to revenue indicates the fixed-cost base is being absorbed, which is the core of operating leverage. However, the near-zero trailing operating margin means the earlier quarters still dominate the cumulative picture. Whether SG&A continues to grow slower than revenue in upcoming periods will determine if this is structural or a transitory quarter.
Quarterly Profit Beat Versus Trailing Losses
Based on EDBL's reported figures, the latest quarter delivered diluted EPS of $1.06 against a trailing net margin of -5.8%, a gap that raises questions about how much of the recent earnings reflects recurring operations.
A single quarter with net income of $35.2M on $57.9M revenue exceeds what operating income alone would suggest, pointing to possible non-operating or tax-related contributions that are not detailed in the provided data. Stock-based compensation of $3.3M is modest relative to net income and does not appear to be distorting results materially. Earnings quality should be treated as provisional until several consecutive quarters confirm the run-rate.
Growth Quality and Margin Sustainability Risks
The strongest bear case is that ETON's 157.9% quarterly growth and 76.5% gross margin may reflect launch timing and one-time items, while trailing net margin of -5.8% and ROE of -18.2% show the business has not yet proven durable profitability.
Short-sellers would likely argue that the 2026Q3 spike coincides with inventory stocking and possible milestone recognition, both of which can inflate a single quarter without signaling sustainable demand. The leverage profile, with debt-to-equity of 1.19, combined with negative returns on equity, suggests the company still depends on external capital structure to fund growth. Investors should monitor whether the next two quarters show revenue holding near current levels and operating income remaining positive.